ACTIONABILITY KNOWLEDGE REPOSITORY ACTIONABILITY CURATION INTERFACE
Update History
Condition: Multiple Endocrine Neoplasia Type I
Gene/Gene Panel: MEN1
Context: Pediatric
Date
Status
Release
Outcomes-Interventions
Notes
2022/02/09
Released
1.1.5
P
Morbidity from other MEN1-related tumors (gastrinoma excluded) (GroupA)
Imaging surveillance (GroupA) 8CB
Biochemical surveillance (GroupA) 9CB
Morbidity from parathyroid adenoma (GroupA)
Biochemical surveillance to guide parathyroidectomy decision (GroupA) 10CB
Internal system migration associated with MONDO name addition.
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
MEN1 ⇔ 0007540 MULTIPLE ENDOCRINE NEOPLASIA, TYPE I; MEN1
Strong Actionability
Strong Actionability
2022/02/09
Released (Under revision)
1.1.4
P
Morbidity from other MEN1-related tumors (gastrinoma excluded) (GroupA)
Imaging surveillance (GroupA) 8CB
Biochemical surveillance (GroupA) 9CB
Morbidity from parathyroid adenoma (GroupA)
Biochemical surveillance to guide parathyroidectomy decision (GroupA) 10CB
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
MEN1 ⇔ 0007540 MULTIPLE ENDOCRINE NEOPLASIA, TYPE I; MEN1
Strong Actionability
Strong Actionability
2021/09/01
Released
1.1.4
P
Morbidity from other MEN1-related tumors (gastrinoma excluded) (GroupA)
Imaging surveillance (GroupA) 8CB
Biochemical surveillance (GroupA) 9CB
Morbidity from parathyroid adenoma (GroupA)
Biochemical surveillance to guide parathyroidectomy decision (GroupA) 10CB
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
MEN1 ⇔ 0007540 MULTIPLE ENDOCRINE NEOPLASIA, TYPE I; MEN1
Strong Actionability
Strong Actionability
2021/09/01
Released (Under revision)
1.1.3
P
Morbidity from other MEN1-related tumors (gastrinoma excluded) (GroupA)
Imaging surveillance (GroupA) 8CB
Biochemical surveillance (GroupA) 9CB
Morbidity from parathyroid adenoma (GroupA)
Biochemical surveillance to guide parathyroidectomy decision (GroupA) 10CB
Corrected MONDO ID to the correct format
2020/05/12
Released
1.1.3
P
Morbidity from other MEN1-related tumors (gastrinoma excluded) (GroupA)
Imaging surveillance (GroupA) 8CB
Biochemical surveillance (GroupA) 9CB
Morbidity from parathyroid adenoma (GroupA)
Biochemical surveillance to guide parathyroidectomy decision (GroupA) 10CB
Corrected MONDO ID to the correct format
2020/05/12
Released (Under revision)
1.1.2
P
Morbidity from other MEN1-related tumors (gastrinoma excluded) (GroupA)
Imaging surveillance (GroupA) 8CB
Biochemical surveillance (GroupA) 9CB
Morbidity from parathyroid adenoma (GroupA)
Biochemical surveillance to guide parathyroidectomy decision (GroupA) 10CB
2020/04/29
Released
1.1.2
P
Morbidity from other MEN1-related tumors (gastrinoma excluded) (GroupA)
Imaging surveillance (GroupA) 8CB
Biochemical surveillance (GroupA) 9CB
Morbidity from parathyroid adenoma (GroupA)
Biochemical surveillance to guide parathyroidectomy decision (GroupA) 10CB
2020/04/29
Released (Under revision)
1.1.1
P
Morbidity from other MEN1-related tumors (gastrinoma excluded) (GroupA)
Imaging surveillance (GroupA) 8CB
Biochemical surveillance (GroupA) 9CB
Morbidity from parathyroid adenoma (GroupA)
Biochemical surveillance to guide parathyroidectomy decision (GroupA) 10CB
2020/04/22
Released
1.1.1
P
Morbidity from other MEN1-related tumors (gastrinoma excluded) (GroupA)
Imaging surveillance (GroupA) 8CB
Biochemical surveillance (GroupA) 9CB
Morbidity from parathyroid adenoma (GroupA)
Biochemical surveillance to guide parathyroidectomy decision (GroupA) 10CB
2020/04/22
Released (Under revision)
1.1.0
P
Morbidity from other MEN1-related tumors (gastrinoma excluded) (GroupA)
Imaging surveillance (GroupA) 8CB
Biochemical surveillance (GroupA) 9CB
Morbidity from parathyroid adenoma (GroupA)
Biochemical surveillance to guide parathyroidectomy decision (GroupA) 10CB
Internal system migration associated with Gene-Disease scoring groups upgrades.
2019/10/03
Released
1.1.0
P
Morbidity from other MEN1-related tumors (gastrinoma excluded) (GroupA)
Imaging surveillance (GroupA) 8CB
Biochemical surveillance (GroupA) 9CB
Morbidity from parathyroid adenoma (GroupA)
Biochemical surveillance to guide parathyroidectomy decision (GroupA) 10CB
Internal system migration associated with Gene-Disease scoring groups upgrades.
2019/05/15
Released
1.0.0
P
Morbidity from other MEN1-related tumors (gastrinoma excluded)
Biochemical surveillance 9CB
Imaging surveillance 8CB
Morbidity from parathyroid adenoma
Biochemical surveillance to guide parathyroidectomy decision 10CB
2019/04/09
In Preparation
N/A
We have begun assessment of the Pediatric context for this topic
¤ Powered by BCM's Genboree.